BR9808804A - Processos para tratar um indivìduo para melhorar o funcionamento do trato gastrointestinal superior incluindo o esÈfago e o estÈmago, para tratar um indivìduo para proliferar o tecido do trato gastrointestinal superior, para identificar peptìdeos utilizável para tratar condições inflamatórias, para identificar peptìdeos, utilizável para evitar ou melhorar as condições inflamatórias, utilizável para identificar peptìdeos capazes de proliferar tecido do trato gastrointestinal superior, para tratar profilaticamente um indivìduo, para melhorar o crescimento do tecido do trato gastrointestinal superior em um mamìfero, e para tratar um indivìduo para melhorar o funcionamento do trato gastrointestinal superior, kit, processos para promover o crescimento de tecido do trato gastrointestinal superior ou células, para tratar um paciente para restaurar o trato gastrointestinal superior, para determinar a atividade de um hormÈnio quando usado em combinação com glp-2, para tratar um indivìduo tendo úlceras peptìdicas - Google Patents

Processos para tratar um indivìduo para melhorar o funcionamento do trato gastrointestinal superior incluindo o esÈfago e o estÈmago, para tratar um indivìduo para proliferar o tecido do trato gastrointestinal superior, para identificar peptìdeos utilizável para tratar condições inflamatórias, para identificar peptìdeos, utilizável para evitar ou melhorar as condições inflamatórias, utilizável para identificar peptìdeos capazes de proliferar tecido do trato gastrointestinal superior, para tratar profilaticamente um indivìduo, para melhorar o crescimento do tecido do trato gastrointestinal superior em um mamìfero, e para tratar um indivìduo para melhorar o funcionamento do trato gastrointestinal superior, kit, processos para promover o crescimento de tecido do trato gastrointestinal superior ou células, para tratar um paciente para restaurar o trato gastrointestinal superior, para determinar a atividade de um hormÈnio quando usado em combinação com glp-2, para tratar um indivìduo tendo úlceras peptìdicas

Info

Publication number
BR9808804A
BR9808804A BR9808804-1A BR9808804A BR9808804A BR 9808804 A BR9808804 A BR 9808804A BR 9808804 A BR9808804 A BR 9808804A BR 9808804 A BR9808804 A BR 9808804A
Authority
BR
Brazil
Prior art keywords
gastrointestinal tract
treat
upper gastrointestinal
individual
improve
Prior art date
Application number
BR9808804-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Daniel J Drucker
Original Assignee
Ontario Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9715481.9A external-priority patent/GB9715481D0/en
Priority claimed from US09/059,504 external-priority patent/US6051557A/en
Application filed by Ontario Inc filed Critical Ontario Inc
Publication of BR9808804A publication Critical patent/BR9808804A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
BR9808804-1A 1997-05-16 1998-05-15 Processos para tratar um indivìduo para melhorar o funcionamento do trato gastrointestinal superior incluindo o esÈfago e o estÈmago, para tratar um indivìduo para proliferar o tecido do trato gastrointestinal superior, para identificar peptìdeos utilizável para tratar condições inflamatórias, para identificar peptìdeos, utilizável para evitar ou melhorar as condições inflamatórias, utilizável para identificar peptìdeos capazes de proliferar tecido do trato gastrointestinal superior, para tratar profilaticamente um indivìduo, para melhorar o crescimento do tecido do trato gastrointestinal superior em um mamìfero, e para tratar um indivìduo para melhorar o funcionamento do trato gastrointestinal superior, kit, processos para promover o crescimento de tecido do trato gastrointestinal superior ou células, para tratar um paciente para restaurar o trato gastrointestinal superior, para determinar a atividade de um hormÈnio quando usado em combinação com glp-2, para tratar um indivìduo tendo úlceras peptìdicas BR9808804A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4675497P 1997-05-16 1997-05-16
GBGB9715481.9A GB9715481D0 (en) 1997-07-23 1997-07-23 Methods of enhancing functioning of the upper gastrointestinal tract
US09/059,504 US6051557A (en) 1997-05-16 1998-04-13 Methods of enhancing functioning of the upper gastrointestinal tract
PCT/CA1998/000497 WO1998052600A1 (en) 1997-05-16 1998-05-15 Methods of enhancing functioning of the upper gastrointestinal tract

Publications (1)

Publication Number Publication Date
BR9808804A true BR9808804A (pt) 2001-09-18

Family

ID=27268946

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9808804-1A BR9808804A (pt) 1997-05-16 1998-05-15 Processos para tratar um indivìduo para melhorar o funcionamento do trato gastrointestinal superior incluindo o esÈfago e o estÈmago, para tratar um indivìduo para proliferar o tecido do trato gastrointestinal superior, para identificar peptìdeos utilizável para tratar condições inflamatórias, para identificar peptìdeos, utilizável para evitar ou melhorar as condições inflamatórias, utilizável para identificar peptìdeos capazes de proliferar tecido do trato gastrointestinal superior, para tratar profilaticamente um indivìduo, para melhorar o crescimento do tecido do trato gastrointestinal superior em um mamìfero, e para tratar um indivìduo para melhorar o funcionamento do trato gastrointestinal superior, kit, processos para promover o crescimento de tecido do trato gastrointestinal superior ou células, para tratar um paciente para restaurar o trato gastrointestinal superior, para determinar a atividade de um hormÈnio quando usado em combinação com glp-2, para tratar um indivìduo tendo úlceras peptìdicas

Country Status (13)

Country Link
EP (1) EP0981362B1 (enExample)
JP (2) JP4699576B2 (enExample)
CN (1) CN1264307B (enExample)
AT (1) ATE253375T1 (enExample)
AU (1) AU746633B2 (enExample)
BR (1) BR9808804A (enExample)
CA (1) CA2289652C (enExample)
DE (1) DE69819488T2 (enExample)
DK (1) DK0981362T3 (enExample)
ES (1) ES2210756T3 (enExample)
MX (1) MXPA99010523A (enExample)
PT (1) PT981362E (enExample)
WO (1) WO1998052600A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE253375T1 (de) * 1997-05-16 2003-11-15 Ontario Inc 1149336 Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes
GB9905416D0 (en) * 1999-03-09 1999-05-05 Allelix Biopharma Small molecules having GLP-2 like activity
RU2164349C1 (ru) * 1999-07-27 2001-03-20 Нижегородская государственная медицинская академия Способ определения стоматологического статуса
WO2001041779A2 (en) * 1999-12-08 2001-06-14 1149336 Ontario Inc. Combined use of glp-2 receptor agonist and chemotherapeutic agent in treatment
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
PT1326630E (pt) * 2000-09-18 2008-09-02 Sanos Bioscience As Utilização de péptidos glp-2
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
DK1809318T3 (da) 2004-11-01 2013-09-08 Nps Pharma Inc Behandling af korttarmssyndrom-patienter med tyktarmskontinuitet
DE602006020123D1 (de) † 2005-05-04 2011-03-31 Zealand Pharma As Glucagon-like-peptide-2- (glp-2-) analoga
AU2007319066B2 (en) * 2006-11-08 2013-09-19 Zealand Pharma A/S Selective glucagon-like-peptide-2 (GLP-2) analogues
US20110171164A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of glp-2-like peptides
JP5908478B2 (ja) * 2010-08-30 2016-04-26 エヌピーエス ファーマシューティカルズ インコーポレイテッドNps Pharmaceuticals, Inc. h「Gly2」GLP−2の固相合成
EA028929B1 (ru) 2012-05-03 2018-01-31 Зилэнд Фарма А/С Аналоги глюкагоноподобного пептида-2 (glp-2)
US20180200301A1 (en) * 2015-05-21 2018-07-19 Shanghai Institutes For Biological Sciences Chinese Academy Of Sciences Low-Oxygen-Treated Mesenchymal Stem Cell and Use Thereof
KR102502040B1 (ko) 2016-12-09 2023-02-24 질랜드 파마 에이/에스 아실화 glp-1/glp-2 이중 효능제
IL271245B2 (en) 2017-06-16 2023-10-01 Zealand Pharma As Dosing regimen for administration of glucagon-like peptide analog (GLP-2) 2
CN108273038B (zh) * 2018-03-16 2019-03-19 中国人民解放军军事科学院军事医学研究院 防治肠型放射病的药物组合物
CN110226566A (zh) * 2019-07-12 2019-09-13 南京中医药大学 一种放射性口腔黏膜炎动物模型的造模方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK27885A (da) * 1985-01-22 1986-07-23 Novo Industri As Fremstilling af peptider
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
EP2275438A1 (en) * 1996-04-12 2011-01-19 1149336 Ontario Inc. Glucagon-like peptide-2 analogs
ES2181054T3 (es) * 1996-12-06 2003-02-16 Amgen Inc Utilizacion de producto(s) proteico(s) kgf y de producto(s) proteico(s) glp-2 para la preparacion de un medicamento.
US5952301A (en) * 1996-12-10 1999-09-14 1149336 Ontario Inc. Compositions and methods for enhancing intestinal function
ATE253375T1 (de) * 1997-05-16 2003-11-15 Ontario Inc 1149336 Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes

Also Published As

Publication number Publication date
ATE253375T1 (de) 2003-11-15
WO1998052600A9 (en) 2000-03-09
DE69819488D1 (de) 2003-12-11
AU746633B2 (en) 2002-05-02
CA2289652A1 (en) 1998-11-26
DE69819488T2 (de) 2004-08-26
ES2210756T3 (es) 2004-07-01
MXPA99010523A (es) 2004-09-01
AU7516398A (en) 1998-12-11
EP0981362A1 (en) 2000-03-01
JP2002502369A (ja) 2002-01-22
EP0981362B1 (en) 2003-11-05
CN1264307B (zh) 2013-10-30
HK1030160A1 (en) 2001-04-27
CN1264307A (zh) 2000-08-23
PT981362E (pt) 2004-03-31
JP2009280598A (ja) 2009-12-03
WO1998052600A1 (en) 1998-11-26
JP4699576B2 (ja) 2011-06-15
CA2289652C (en) 2012-02-28
DK0981362T3 (da) 2004-03-15

Similar Documents

Publication Publication Date Title
Bienenstock et al. The role of mast cells in inflammatory processes: evidence for nerve/mast cell interactions
PT944396E (pt) Composicoes e processos para melhorar o funcionamento gastrointestinal
Di Mario et al. Use of bovine lactoferrin for Helicobacter pylori eradication
PT981362E (pt) Metodos de melhoramento do funcionamento do tracto gastrointestinal superior
Hulshof et al. Double-blind, placebo-controlled study of oral calcitriol for the treatment of localized and systemic scleroderma
Leis et al. Facilitated neurogenic inflammation in unaffected limbs of patients with complex regional pain syndrome
Wormsley Response to duodenal acidification in man: III. Comparison with the effects of secretin and pancreozymin
ATE451929T1 (de) Von casein abgeleitete peptide und deren anwendung für die therapie
KR101514414B1 (ko) 당뇨병성 족부 궤양의 치료방법
Holle et al. Vagotomy: latest advances with special reference to gastric and duodenal ulcers disease
US20050261194A1 (en) Use of thymulin-like peptides for making pain-relieving medicines
BR9607336A (pt) Composições de aminoácidos e utilidades das mesmas em nutrição clinica
Pan et al. Cytokine transport across the injured blood-spinal cord barrier
Nustede et al. Plasma concentrations of neurotensin and CCK in patients with chronic pancreatitis with and without enzyme substitution
BR0111506A (pt) Complexos de droga macromoleculares e composições contendo os mesmos
ATE425763T1 (de) Verwendung von zusammensetzungen mit der biologischen aktivitat der vasoaktiven intestinalen peptide zur behandlung von sarcoidose
Joffe et al. Increased muscle calcium A possible cause of mitochondrial dysfunction and cellular necrosis in denervated rat skeletal muscle
Fukuda et al. Adrenomedullin promotes epithelial restitution of rat and human gastric mucosa in vitro
Largiadèr Proximal selective vagotomy without pyloroplasty: a randomized clinical study
Mendizabal et al. Effects of spermine on water absorption, polyethylene glycol 4000 permeability and collagenase activity in rat descending colon in vivo
WO2022010942A3 (en) Combination therapies for the treatment and prevention of biofilms
Stoupel et al. Beta‐Endorphins in acute myocardial infarction
Rodriguez et al. Current trends in pressure ulcer research
Alharbi The Effect of Lower Limb Neuromuscular Electrical Stimulation on the Muscle and Metabolic Health After Acute Spinal Cord Injury
Arcangeli et al. Effective treatment of osteoarthritis with a 150 mg prolonged-release of diclofenac sodium

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 37, OPINO PELO INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE: NAO ATENDE AO REQUISITO DE ATIVIDADE INVENTIVA (ART. 8O COMBINADO COM O ART. 13 DA LPI 9279/96); AS REIVINDICACOES ESTAO INDEFINIDAS E/OU NAO ESTAO FUNDAMENTADAS NO RELATORIO DESCRITIVO (ART. 25 DA LPI); NAO E CONSIDERADO INVENCAO, UMA VEZ QUE INCIDE NO ART. 10 (INCISO VIII) DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 38/27 (2006.01), A61K 38/26 (2006.0